Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Myeloid Neoplasm: early-phase trial registry

4 of 8 indexed Myeloid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Myeloid Neoplasm: 8 US clinical trials tracked, 4 recruiting.

Myeloid Neoplasm is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 2 of these trials.

Enrollment posture brief

Registry condition myeloid-neoplasm

OPEN 4 | RECR 50% | LATE 1 | EARLY 5 | RANK #2176 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Activity, Motor75%Achalasia50%Myeloid Neoplasm (this)50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Myeloid Neoplasm

Myeloid Neoplasm lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Myeloid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Myeloid Neoplasm is recruiting above its size-band peers.

    4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Myeloid Neoplasm research.

    University of Washington accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Myeloid Neoplasm trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.

  4. Myeloid Neoplasm research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23Phase 31

Open and recent trials

8 total, page 1 of 1

RECRUITING NA 170 participants

A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms

University of Rochester

NCT04981821

RECRUITING Phase 1 62 participants

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

University of Washington

NCT04797767

RECRUITING NA 50 participants

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

University of Washington

NCT06710418

RECRUITING Phase 2 37 participants

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Franziska Wachter

NCT05796570

ACTIVE NOT RECRUITING Phase 3 1,645 participants

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

NCT01371981

ACTIVE NOT RECRUITING Phase 2 60 participants

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Fred Hutchinson Cancer Center

NCT04195945

ACTIVE NOT RECRUITING Phase 1 40 participants

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

NCT03862157

ACTIVE NOT RECRUITING Phase 2 25 participants

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

St. Jude Children's Research Hospital

NCT05656248

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Myeloid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cytarabine Drug
3 trials
Mitoxantrone Drug
2 trials
Recombinant Granulocyte Colony-Stimulating Factor Biological
2 trials
Cladribine Drug
2 trials
Venetoclax Drug
2 trials
MHA Drug
1 trials
Asparaginase Drug
1 trials
Pevonedistat Drug
1 trials

US sites by state

Facility locations filed on Myeloid Neoplasm trials. A trial with sites in several states counts in each.

Washington 3 trials
Texas 1 trials
Tennessee 1 trials
New York 1 trials
Massachusetts 1 trials
California 1 trials
Arizona 1 trials
Arkansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Myeloid Neoplasm page

8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myeloid Neoplasm condition card totals 8 registered trials; most-linked intervention Cytarabine; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.